Table 3. Baseline clinical and pathological characteristics of patients diagnosed with uterine cervical cancer.
| Risk factors | Total No. (%*) |
Cerebral metastasis | p-value | |||
|---|---|---|---|---|---|---|
| Yes No. (%†) |
No No. (%†) |
Univariate analysis cOR (95%CI) |
||||
| Histology | ||||||
| Squamous cell carcinoma | 2,656 (78.2) | 23 (0.9) | 2,633 (99.1) | Reference | ||
| Adenocarcinoma | 589 (17.3) | 14 (2.4) | 575 (97.6) | 2.79 (1.43–5.45) | 0.003 | |
| Adenosquamous carcinoma | 107 (3.15) | 6 (5.6) | 101 (94.4) | 6.80 (2.71–17.07) | <0.001 | |
| Undifferentiated carcinoma | 20 (0.6) | 3 (15) | 17 (85) | 20.20 (5.54–73.70) | <0.001 | |
| Neuroendocrine carcinoma | 25 (0.75) | 5 (20) | 20 (80) | 28.62 (9.89–82.81) | <0.001 | |
| Clinical stage | ||||||
| I | 864 (25.4) | 5 (0.6) | 859 (99.4) | Reference | ||
| II | 1,052 (31.0) | 13 (1.2) | 1,039 (98.8) | 2.15 (0.76–6.05) | 0.147 | |
| III | 1,177 (34.6) | 22 (1.8) | 1,155 (98.2) | 3.27 (1.23–8.68) | 0.017 | |
| IV | 251 (7.4) | 11 (4.0) | 240 (96.0) | 7.87 (2.71–22.88) | <0.001 | |
| Missing | 53 (1.6) | 0 | 53 | ‡ | 0.998 | |
| Primary tumor treatment | ||||||
| Surgery | 740 (21.8) | 4 (0.5) | 736 (99.5) | Reference | ||
| Chemo-radiotherapy | 2,095 (61.7) | 38 (1.8) | 2,057 (98.2) | 3.4 (1.2–9.6) | 0.020 | |
| Other | 562 (16.5) | 9 (1.6) | 553 (98.4) | 3.0 (0.9–9.8) | 0.069 | |
| Metastasis prior to cerebral metastasis | ||||||
| None | 2,935 (86.4) | 31 (1.1) | 2,904 (98.9) | Reference | ||
| 1 metastasis site | 328 (9.7) | 13 (4.0) | 315 (96.0) | 3.87 (2.00–7.46) | <0.001 | |
| 2 or + metastasis sites | 134 (3.9) | 7 (5.2) | 127 (94.8) | 5.16 (2.23–11.95) | <0.001 | |
| Previous bone and cartilage metastasis | ||||||
| Yes | 218 (6.4) | 7 (3.2) | 211 (96.8) | 2.36 (1.05–5.31) | 0.037 | |
| No | 3,179 (93.6) | 44 (1.4) | 3,135 (98.6) | Reference | ||
| Previous lymph node metastasis | ||||||
| Yes | 140 (4.1) | 6 (4.3) | 134 (95.7) | 3.20 (1.34–7.62) | 0.009 | |
| No | 3,257 (95.9) | 45 (1.4) | 3,212 (98.6) | Reference | ||
| Previous lung metastasis | ||||||
| Yes | 137 (4.0) | 12 (8.8) | 125 (91.2) | 7.93 (4.05–15.51) | <0.001 | |
| No | 3,260 (96.0) | 39 (1.2) | 3,221 (98.8) | Reference | ||
| Previous liver metastasis | ||||||
| Yes | 58 (1.7) | 1 (1.7) | 57 (98.3) | 1.15 (0.16–8.509) | 0.888 | |
| No | 3,339 (98.3) | 50 (1.5) | 3,289 (98.5) | Reference | ||
| Previous soft tissue retroperitoneum and peritoneum metastasis | ||||||
| Yes | 56 (1.6) | 2 (3.6) | 54 (96.4) | 2.49 (0.59–10.49) | 0.214 | |
| No | 3,341 (98.4) | 49 (1.5) | 3,292 (98.5) | Reference | ||
| Previous metastasis in other locations | ||||||
| Yes | 78 (2.3) | 2 (2.6) | 76 (97.4) | 1.76 (0.42–7.35) | 0.441 | |
| No‡ | 3,319 (97.7) | 49 (1.5) | 3,270 (98.5) | Reference | ||
| Total | 3,397 (100.0) | 51 (1.5) | 3,346 (98.5) | - | - | |
Statistically significant differences are displayed in bold (p<0.05).
cOR, crude odds ratio; CI = confidence interval.
*Column percentages; †Row percentages; ‡Other metastasis locations: other central nervous system locations (n=9), ovary (n=6), colon and rectum (n=5), vulva (n=3), skin (n=2), heart, mediastinum and pleura (n=2), bladder (n=1), pancreas (n=1); ‡Not available.